HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab ginseng

This article was originally published in The Tan Sheet

Executive Summary

Ten of 12 ginseng supplements evaluated met CL standards for quality, label claims, disintegration and lack of contaminants and adulterants, online testing company announces Aug. 28. MotherNature.com's Korean ginseng had high levels of the pesticides hexachlorobenzene, quintozene, lindane, while Royal King's Chinese ginseng contained less than 10% of the claimed amount of ginsenosides, CL reports. Nature's Way herbal single Korean ginseng and Vitamin World's Chinese red ginseng were among the products that contained the proper amount of ginsenosides and that did not exceed acceptable levels of contaminants. CL last tested ginseng supplements in July 2000; the firm's findings of pesticide contamination in eight of 22 brands tested were featured on ABC News' 20/20 (1"The Tan Sheet" July 17, 2000, p. 15)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel